Brandon G Busbee

Cataract surgery cost utility revisited in 2012: a new economic paradigm.

Gary C. Brown, Gary C Brown, B. Busbee, 2013, Ophthalmology.

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.

Allen C Ho, A. Ho, Roman G. Rubio, 2013, Ophthalmology.

Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.

Allen C Ho, A. Ho, C. Regillo, 2014, Ophthalmology.